Search results

This study is part of the Seek, Test, Treat and Retain (STTR) Collaboration Project that involved over twenty studies in the fields of HIV and drug abuse. All studies were independently developed, but were chosen for the collaboration because they focused on one or more steps of the HIV treatment cascade: Seek, Test, Treat and Retain. As part of STTR Collaboration Project, the studies were grouped into Criminal Justice-related studies and Vulnerable Population-related studies. The data collected by these studies included twelve common domains (e.g., Demographic characteristics, Mental Health) in each of which a shared questionnaire or instrument was taken up by the studies and adapted to fit the study.

Using a randomized controlled study design, this study tested the efficacy of an abstinence-reinforcing CM intervention compared with a control condition (performance feedback) on HIV viral load (VL) suppression. The intervention CM group could receive up to $1320 in vouchers over the 16-week intervention based on drug-free urine. Participants were followed for 28 weeks (44 visits), with research visits occurring twice weekly during the Baseline Period (weeks 1-4, visits 1-8) and Intervention Period (weeks 5-20, visits 9-40), then every two weeks during the Post-Intervention Period (weeks 21-28, visits 41-44).

Substance dependence (SD) is a chronic disease that requires specialty drug and alcohol treatment, primary care (PC), and management of related problems. Although patients with SD may be linked with specialty care and PC, their health care often remains episodic and fragmented, rather than longitudinal, comprehensive, integrated, and coordinated. As a result, adults with SD often enter addiction treatment later and require acute medical care, rather than entering the system earlier when interventions of lower intensity but longer duration might prevent catastrophes. Chronic disease management (CDM) is a collaborative, longitudinal approach to treatment of certain chronic medical illnesses proven to be more effective than routine care. CDM addresses individual patient and health systems barriers to receipt of needed treatment. However, the effectiveness of CDM for SD has not been tested. The objective of this Addiction Health Evaluation and Disease management (AHEAD) study, was to test the effectiveness of CDM for SD in PC.

Subject identification and recruitment occurred primarily at a local detoxification center, as well as by self and physician referral from the Boston Medical Center primary and ambulatory care clinics, emergency department, urgent care center, inpatient settings, and the community. The study enrolled 320 adults with drug dependence and 320 adults with alcohol dependence who were not in SD treatment, and randomized them to a SD CDM program (the AHEAD Clinic) integrated into a real-world PC clinic or to referral to standard PC. All subjects were assessed regarding SD diagnosis, substance use and problems, readiness to change, health-related quality of life, and medical and drug treatment utilization. Subjects were evaluated 3, 6, and 12 months later, and health services utilization data were collected for 2 years from a statewide database. Additionally, in order to better understand and explain the implementation and fidelity of the AHEAD Clinic, the primary care providers (PCPs) of AHEAD Clinic patients were surveyed. Each PCP was presented with a letter from the Principal Investigator explaining the purpose of the survey, the reason why s/he was being asked to complete the survey, compensation for completing the survey, and details about confidentiality and anonymity. The survey itself consisted of questions asking providers about their satisfaction and their attitudes towards caring for patients with alcohol and drug problems, their knowledge of services that the AHEAD Clinic provides, and their experience working with the AHEAD Clinic.

Primary outcomes were illicit drug use, alcohol use, substance-related problems, emergency department visits, and hospitalizations. The proposal's hypothesis was that compared with standard care, a health services delivery intervention (CDM for SD integrated in PC) would decrease alcohol and illicit drug use and related problems, and improve health care utilization patterns. Improved outcomes using the AHEAD approach would support the adoption of a health services delivery strategy, CDM, to better care for patients with SD.

• Dataset 1: 844 variables; 563 cases
• Dataset 2: 607 variables; 500 cases
• Dataset 3: 607 variables; 487 cases
• Dataset 4: 713 variables; 532 cases
• Dataset 5: 80 variables; 549 cases
• Dataset 6: 59 variables; 1,435 cases
• Dataset 7: 25 variables; 87 cases
• Dataset 8: 25 variables; 87 cases
• Dataset 9: 41 variables; 73 cases
• Dataset 10: 9 variables; 11,018 cases
• Dataset 11: 5 variables; 511 cases

The University of Buffalo Adolescent and Family Development Project (AFDP) includes a community sample of adolescents assessed in a 9-wave longitudinal study between 2007 and 2017. The 387 adolescents were 11-12 year old children at recruitment and were assessed annually. The data provide an opportunity to examine risk and protective factors from multiple levels of influences (individual differences, family, peers, community) that might contribute to adolescent substance use in order to inform the development of comprehensive preventive interventions for at-risk youth. The project was largely focused on understanding the development of an internalizing pathway to initiation and escalation of substance use, and eventual development of use-related problems. This was done by examining: 1) the intersection of externalizing and internalizing problems, 2) peer context and use-related motives as a potential mediating mechanism, and 3) whether motivational aspects of personality moderated the proposed mediational paths. Also of interest was whether risk for an internalizing pathway to substance use varied by chronological age or stage of use.

This collection is organized into 13 data parts. Waves 1 through 3 and Waves 7 through 9 each contain 2 datasets pertaining to either a child (DS1, DS3, DS5, DS8, DS10, DS12) or caretaker (DS2, DS4, DS6, DS9, DS11, DS13) interview. All child interview data from Waves 4 through 6 are contained in DS7. Various demographic information, such as age, gender, race, and ethnicity, is also included in the data.

The Adolescent Substance Abuse Prevention Study (ASAPS) was a randomized field trial designed to test the effectiveness of a new school-based substance abuse prevention program called Take Charge of Your Life (TCYL). The program consisted of two curricula, one for middle schools and the other for high schools, which were delivered through the Drug Abuse Resistance Education network of law enforcement officers (D.A.R.E.). TCYL was developed building on existing D.A.R.E. seventh/eighth grade and tenth/eleventh grade curricula and applied principles and strategies suggested by published literature on effective drug abuse prevention programming and effective middle and high school curricula design. ASAPS was conducted among a 2001-2002 multi-site cohort of seventh graders who were followed for five years until the 2005-2006 school year when they were in the eleventh grade. The first TCYL curriculum was delivered in the treatment schools when the students were in seventh grade and the second was delivered when they were in the ninth grade.

Over the five-year study period, the treatment and control students responded to seven self-administered surveys: (1) at baseline in the seventh grade, (2) post-intervention in the seventh grade, (3) in the eighth grade, (4) pre-intervention in the ninth grade, (5) post-intervention in the ninth grade, (6) in the tenth grade, and (7) in the eleventh grade. Topics covered by the surveys include normative beliefs, social skills, attitudes toward drug use, and self-reported use of alcohol, tobacco, marijuana, and other illicit drugs. The ASAPS data also include measures of implementation fidelity of the seventh and ninth grade TCYL curricula, which were obtained from trained observers who rated the D.A.R.E. officers' delivery in the classroom. The fidelity measures encompass content coverage and instructional strategy.

This data collection comprises two data files, both with public- and restricted-use versions. The first (the Main Data File) contains the students' survey responses and the seventh grade curriculum fidelity measures, while the second (the 9th Grade Officer Observations Data) contains the ninth grade curriculum fidelity measures.

The Community Vulnerability and Responses to Drug-User-Related HIV/AIDS, 1990-2013 [96 Metropolitan Statistical Areas, United States] study (CVAR) was a research study of why large United States Metropolitan Statistical Areas (MSAs) vary over time in their vulnerability to HIV/AIDS among drug users and in MSA responses to HIV/AIDS. This collection contains estimates of HIV prevalence among people who injected drugs (PWID) and among sub-populations of PWID. This collection is comprised of ten datasets with differing amounts of variables and provides trend data that describe the following:

• Epidemiologic outcomes including population prevalence of PWIDs and Non-injecting drug users (NIDUs), and particularly their prevalence among youth; and, among PWIDs, HIV prevalence, late-diagnosis HIV cases, and AIDS incidence and mortality.
• Implementation of evidence-based drug-related interventions including drug abuse treatment, syringe exchange, HIV counseling and testing.
• Implementation of non-evidence-based drug-related interventions including incarceration and arrests of drug users.

The collection contains data on the MSA sub-populations including Black, Hispanic, White and "other" race categories. In addition, some statistics are presented in age range categories such as ages 15-29, 30-64 and 15-64.

In 2002, the National Institute on Drug Abuse (NIDA) funded the Criminal Justice Drug Abuse Treatment Studies (CJ-DATS) cooperative agreement. The Institute of Behavioral Research at Texas Christian University (TCU) was one of nine National Research Centers selected to study current drug treatment practices and outcomes in correctional settings and to examine strategies for improving treatment services for drug-involved offenders.

The specific aims of the PIC study were to:

1. Cross sectionally test and adapt the TCU CJ-CEST, BOP, and NDRI CAI assessments for use in multiple correctional settings;
2. To examine agency and program records of client progress relevant to treatment process; and to
3. Revise the assessments as necessary for use in longitudinal assessment protocols and CJ Management Information Systems (MIS).

During the first data collection period, Wave 1, a total of 3,266 inmates were surveyed from research centers based out of Texas Christian University, the University of Delaware, the University of Kentucky, University of California, Los Angeles (UCLA), and the National Development and Research Institute (NDRI). After psychometrics were run and the forms revised slightly, a second administration took place but this time only at two centers (TCU and Delaware). During Wave 2 a total of 1,421 clients participated in the survey.

The Detroit Neighborhood Health Study (DNHS) is a prospective, representative longitudinal cohort study of predominantly African American adults living in Detroit, Michigan. The main purpose of the study was to determine the predictive effects of ecological stressors, such as income distribution and residential segregation, on the development of post-traumatic stress disorder (PTSD), substance use, and other psychological and behavioral outcomes. An additional purpose was to study the interrelationships between ecological stressors, exposure to potentially traumatic events (PTEs), PTSD, substance use, and immune function. The study team hypothesized that exposure to ecological stressors would influence the risk of PTE exposure, PTSD, substance use, other psychological outcomes, and the relationships between these factors.

The current collection includes data from all 5 waves of the study. Cohort participants were initially recruited in 2008 with a dual-frame probability design, using telephone numbers obtained from the U.S. Postal Service Delivery Sequence Files as well as a listed-assisted random-digit-dial frame. Individuals without listed landlines or telephones and individuals with only a cell phone listed were invited to participate through a postal mail effort. Participants completed a 40 minute, structured telephone interview annually between 2008-2012 to assess perceptions of participants' neighborhoods, mental and physical health status, social support, exposure to traumatic events, and alcohol and tobacco use. In addition, the study team completed a structured assessment of Detroit's 54 neighborhoods in order to describe the characteristics of respondents' neighborhoods. The assessment included information about the quality of housing exteriors; presence of graffiti, abandoned cars, alcohol and tobacco advertisements, and security warning signs; presence of vacant buildings; and street and traffic noise levels.

All survey participants were offered the opportunity to provide a blood specimen (venipuncture, blood spot, or saliva) for immune and inflammatory marker testing as well as genetic testing of DNA. Participants received an additional $25USD if they elected to give a sample. Informed consent was obtained at the beginning of each interview and again at specimen collection. However, these specimens are not included as part of this data collection.

For more information about the study, please visit the Detroit Neighborhood Health Study website.

Genotypic data from DNHS are available on the NIH database of Genotypes and Phenotypes (dbGaP).

These data are part of NACJD's Fast Track Release and are distributed as they were received from the data depositor. The files have been zipped by NACJD for release, but not checked or processed except for the removal of direct identifiers. Users should refer to the accompanying readme file for a brief description of the files available with this collection and consult the investigator(s) if further information is needed.

This study examined etiological pathways to teen dating violence (TDV) in a sample of adolescents who had been followed since infancy and were at high-risk due to parental alcohol problems. Adolescents (M=17.68 years of age) who had been participating, along with their parents, in a longitudinal study of the effects of parental alcohol problems on child development completed an additional wave of survey data in 11-12th grades. Families (N=227) were initially recruited from county birth records when the child was 12 months of age and had been previously assessed at 12-, 18-, 24-, 36-months, kindergarten, 4th, 6th, and 8th grades. For the current wave of data collection, adolescent participants (n=185) used computer-assisted interviewing to complete questionnaires assessing their individual characteristics, family and peer relationships, substance use, dating behaviors and involvement in TDV as a victim or perpetrator.

In the fall of 1993, the entering 1st graders in nine Baltimore City, Maryland public elementary schools were recruited for participation in a randomized trial of two universal, preventive interventions. Both interventions targeted the early antecedent risk behaviors of poor academic achievement and aggressive/coercive behavior and their distal correlates: substance abuse/dependence, antisocial behavior, high risk sexual behavior, sexually transmitted infections (STIs), and psychiatric symptoms and disorders. One intervention, the classroom-centered intervention (CC), sought to reduce the early risk behaviors of poor achievement and aggressive/coercive behaviors through the enhancement of classroom curricula and teacher instructional and behavior management practices. The second intervention, the family-school partnership intervention (FSP), sought to reduce these early risk behaviors by improving parent-teacher/school mental health professional collaboration and by enhancing parents' teaching and behavior management skills. The participating students and 1st grade teachers were randomly assigned to either the CC or FSP classroom-level conditions or to a control or standard setting classroom. The participating students' outcomes were assessed from the fall of 1st grade through 12th grade. Annual outcome assessments continued following high school through age ~ 26. Data from participating students' self-report of substance use and its putative mediators and moderators in 8th through 12th grade are available in this dataset.

The principal investigator withheld the intervention status variable that distinguishes the intervention groups from the control group. You may contact the Principal investigator to discuss obtaining the intervention variable.

This dataset contains variables on frequency of respondents' substance use during the respondents' lifetime as well as in the year, month, week prior to the survey. In addition, the dataset contains variables on alcohol consumption. The dataset also contains variables on the respondents' perceptions of the availability and harmfulness of substances. Respondents were also asked about perception of how many of his/her friends used drugs as well as their attitudes towards drug use, including personal disapproval of drug use, and perceived attitudes of parents and friends towards the respondents' drug use. Respondents were asked whether and how often they were offered substances to use and their intention to use substances if offered in the future. Substances asked about include tobacco, alcohol, marijuana, cocaine, crack, heroin, ecstasy, and inhalants.

This dataset contains 1535 variables and 713 respondents. The only demographic variables in this dataset are race and gender.

The Drug Abuse Warning Network (DAWN) is a nationally representative public health surveillance system that has monitored drug related emergency department (ED) visits to hospitals since the early 1970s. First administered by the Drug Enforcement Administration (DEA) and the National Institute on Drug Abuse (NIDA), the responsibility for DAWN now rests with the Substance Abuse and Mental Health Services Administration's (SAMHSA) Center for Behavioral Health Statistics and Quality (CBHSQ). Over the years, the exact survey methodology has been adjusted to improve the quality, reliability, and generalizability of the information produced by DAWN. The current approach was first fully implemented in the 2004 data collection year.

DAWN relies on a longitudinal probability sample of hospitals located throughout the United States. To be eligible for selection into the DAWN sample, a hospital must be a non-Federal, short-stay, general surgical and medical hospital located in the United States, with at least one 24-hour ED. DAWN cases are identified by the systematic review of ED medical records in participating hospitals. The unit of analysis is any ED visit involving recent drug use. DAWN captures both ED visits that are directly caused by drugs and those in which drugs are a contributing factor but not the direct cause of the ED visit. The reason a patient used a drug is not part of the criteria for considering a visit to be drug related. Therefore, all types of drug-related events are included: drug misuse or abuse, accidental drug ingestion, drug-related suicide attempts, malicious drug poisonings, and adverse reactions. DAWN does not report medications that are unrelated to the visit.

The DAWN public-use dataset provides information for all types of drugs, including illegal drugs, prescription drugs, over-the-counter medications, dietary supplements, anesthetic gases, substances that have psychoactive effects when inhaled, alcohol when used in combination with other drugs (all ages), and alcohol alone (only for patients aged 20 or younger). Public-use dataset variables describe and categorize up to 16 drugs contributing to the ED visit, including toxicology confirmation and route of administration. Administrative variables specify the type of case, case disposition, categorized episode time of day, and quarter of year. Metropolitan area is included for represented metropolitan areas. Created variables include the number of unique drugs reported and case-level indicators for alcohol, non-alcohol illicit substances, any pharmaceutical, non-medical use of pharmaceuticals, and all misuse and abuse of drugs. Demographic items include age category, sex, and race/ethnicity. Complex sample design and weighting variables are included to calculate various estimates of drug-related ED visits for the Nation as a whole, as well as for specific metropolitan areas, from the ED visits classified as DAWN cases in the selected hospitals.

The Drug Abuse Warning Network (DAWN) is a nationally representative public health surveillance system that has monitored drug related emergency department (ED) visits to hospitals since the early 1970s. First administered by the Drug Enforcement Administration (DEA) and the National Institute on Drug Abuse (NIDA), the responsibility for DAWN now rests with the Substance Abuse and Mental Health Services Administration's (SAMHSA) Center for Behavioral Health Statistics and Quality (CBHSQ). Over the years, the exact survey methodology has been adjusted to improve the quality, reliability, and generalizability of the information produced by DAWN. The current approach was first fully implemented in the 2004 data collection year.

DAWN relies on a longitudinal probability sample of hospitals located throughout the United States. To be eligible for selection into the DAWN sample, a hospital must be a non-Federal, short-stay, general surgical and medical hospital located in the United States, with at least one 24-hour ED. DAWN cases are identified by the systematic review of ED medical records in participating hospitals. The unit of analysis is any ED visit involving recent drug use. DAWN captures both ED visits that are directly caused by drugs and those in which drugs are a contributing factor but not the direct cause of the ED visit. The reason a patient used a drug is not part of the criteria for considering a visit to be drug related. Therefore, all types of drug-related events are included: drug misuse or abuse, accidental drug ingestion, drug-related suicide attempts, malicious drug poisonings, and adverse reactions. DAWN does not report medications that are unrelated to the visit.

The DAWN public-use dataset provides information for all types of drugs, including illegal drugs, prescription drugs, over-the-counter medications, dietary supplements, anesthetic gases, substances that have psychoactive effects when inhaled, alcohol when used in combination with other drugs (all ages), and alcohol alone (only for patients aged 20 or younger). Public-use dataset variables describe and categorize up to 16 drugs contributing to the ED visit, including toxicology confirmation and route of administration. Administrative variables specify the type of case, case disposition, categorized episode time of day, and quarter of year. Metropolitan area is included for represented metropolitan areas. Created variables include the number of unique drugs reported and case-level indicators for alcohol, non-alcohol illicit substances, any pharmaceutical, non-medical use of pharmaceuticals, and all misuse and abuse of drugs. Demographic items include age category, sex, and race/ethnicity. Complex sample design and weighting variables are included to calculate various estimates of drug-related ED visits for the Nation as a whole, as well as for specific metropolitan areas, from the ED visits classified as DAWN cases in the selected hospitals.

The Drug Abuse Warning Network (DAWN) is a nationally representative public health surveillance system that has monitored drug related emergency department (ED) visits to hospitals since the early 1970s. First administered by the Drug Enforcement Administration (DEA) and the National Institute on Drug Abuse (NIDA), the responsibility for DAWN now rests with the Substance Abuse and Mental Health Services Administration's (SAMHSA) Center for Behavioral Health Statistics and Quality (CBHSQ). Over the years, the exact survey methodology has been adjusted to improve the quality, reliability, and generalizability of the information produced by DAWN. The current approach was first fully implemented in the 2004 data collection year.

DAWN relies on a longitudinal probability sample of hospitals located throughout the United States. To be eligible for selection into the DAWN sample, a hospital must be a non-Federal, short-stay, general surgical and medical hospital located in the United States, with at least one 24-hour ED. DAWN cases are identified by the systematic review of ED medical records in participating hospitals. The unit of analysis is any ED visit involving recent drug use. DAWN captures both ED visits that are directly caused by drugs and those in which drugs are a contributing factor but not the direct cause of the ED visit. The reason a patient used a drug is not part of the criteria for considering a visit to be drug related. Therefore, all types of drug-related events are included: drug misuse or abuse, accidental drug ingestion, drug-related suicide attempts, malicious drug poisonings, and adverse reactions. DAWN does not report medications that are unrelated to the visit.

The DAWN public-use dataset provides information for all types of drugs, including illegal drugs, prescription drugs, over-the-counter medications, dietary supplements, anesthetic gases, substances that have psychoactive effects when inhaled, alcohol when used in combination with other drugs (all ages), and alcohol alone (only for patients aged 20 or younger). Public-use dataset variables describe and categorize up to 16 drugs contributing to the ED visit, including toxicology confirmation and route of administration. Administrative variables specify the type of case, case disposition, categorized episode time of day, and quarter of year. Metropolitan area is included for represented metropolitan areas. Created variables include the number of unique drugs reported and case-level indicators for alcohol, non-alcohol illicit substances, any pharmaceutical, non-medical use of pharmaceuticals, and all misuse and abuse of drugs. Demographic items include age category, sex, and race/ethnicity. Complex sample design and weighting variables are included to calculate various estimates of drug-related ED visits for the Nation as a whole, as well as for specific metropolitan areas, from the ED visits classified as DAWN cases in the selected hospitals.

The Drug Abuse Warning Network (DAWN) is a nationally representative public health surveillance system that has monitored drug related emergency department (ED) visits to hospitals since the early 1970s. First administered by the Drug Enforcement Administration (DEA) and the National Institute on Drug Abuse (NIDA), the responsibility for DAWN now rests with the Substance Abuse and Mental Health Services Administration's (SAMHSA) Center for Behavioral Health Statistics and Quality (CBHSQ). Over the years, the exact survey methodology has been adjusted to improve the quality, reliability, and generalizability of the information produced by DAWN. The current approach was first fully implemented in the 2004 data collection year.

DAWN relies on a longitudinal probability sample of hospitals located throughout the United States. To be eligible for selection into the DAWN sample, a hospital must be a non-federal, short-stay, general surgical and medical hospital located in the United States, with at least one 24-hour ED. DAWN cases are identified by the systematic review of ED medical records in participating hospitals. The unit of analysis is any ED visit involving recent drug use. DAWN captures both ED visits that are directly caused by drugs and those in which drugs are a contributing factor but not the direct cause of the ED visit. The reason a patient used a drug is not part of the criteria for considering a visit to be drug related. Therefore, all types of drug-related events are included: drug misuse or abuse, accidental drug ingestion, drug-related suicide attempts, malicious drug poisonings, and adverse reactions. DAWN does not report medications that are unrelated to the visit.

The DAWN public-use dataset provides information for all types of drugs, including illegal drugs, prescription drugs, over-the-counter medications, dietary supplements, anesthetic gases, substances that have psychoactive effects when inhaled, alcohol when used in combination with other drugs (all ages), and alcohol alone (only for patients aged 20 or younger). Public-use dataset variables describe and categorize up to 16 drugs contributing to the ED visit, including toxicology confirmation and route of administration. Administrative variables specify the type of case, case disposition, categorized episode time of day, and quarter of year. Metropolitan area is included for represented metropolitan areas. Created variables include the number of unique drugs reported and case-level indicators for alcohol, non-alcohol illicit substances, any pharmaceutical, non-medical use of pharmaceuticals, and all misuse and abuse of drugs. Demographic items include age category, sex, and race/ethnicity. Complex sample design and weighting variables are included to calculate various estimates of drug-related ED visits for the Nation as a whole, as well as for specific metropolitan areas, from the ED visits classified as DAWN cases in the selected hospitals.

The Drug Abuse Warning Network (DAWN) is a nationally representative public health surveillance system that has monitored drug related emergency department (ED) visits to hospitals since the early 1970s. First administered by the Drug Enforcement Administration (DEA) and the National Institute on Drug Abuse (NIDA), the responsibility for DAWN now rests with the Substance Abuse and Mental Health Services Administration's (SAMHSA) Center for Behavioral Health Statistics and Quality (CBHSQ). Over the years, the exact survey methodology has been adjusted to improve the quality, reliability, and generalizability of the information produced by DAWN. The current approach was first fully implemented in the 2004 data collection year.

DAWN relies on a longitudinal probability sample of hospitals located throughout the United States. To be eligible for selection into the DAWN sample, a hospital must be a non-Federal, short-stay, general surgical and medical hospital located in the United States, with at least one 24-hour ED. DAWN cases are identified by the systematic review of ED medical records in participating hospitals. The unit of analysis is any ED visit involving recent drug use. DAWN captures both ED visits that are directly caused by drugs and those in which drugs are a contributing factor but not the direct cause of the ED visit. The reason a patient used a drug is not part of the criteria for considering a visit to be drug related. Therefore, all types of drug-related events are included: drug misuse or abuse, accidental drug ingestion, drug-related suicide attempts, malicious drug poisonings, and adverse reactions. DAWN does not report medications that are unrelated to the visit.

The DAWN public-use dataset provides information for all types of drugs, including illegal drugs, prescription drugs, over-the-counter medications, dietary supplements, anesthetic gases, substances that have psychoactive effects when inhaled, alcohol when used in combination with other drugs (all ages), and alcohol alone (only for patients aged 20 or younger). Public-use dataset variables describe and categorize up to 16 drugs contributing to the ED visit, including toxicology confirmation and route of administration. Administrative variables specify the type of case, case disposition, categorized episode time of day, and quarter of year. Metropolitan area is included for represented metropolitan areas. Created variables include the number of unique drugs reported and case-level indicators for alcohol, non-alcohol illicit substances, any pharmaceutical, non-medical use of pharmaceuticals, and all misuse and abuse of drugs. Demographic items include age category, sex, and race/ethnicity. Complex sample design and weighting variables are included to calculate various estimates of drug-related ED visits for the Nation as a whole, as well as for specific metropolitan areas, from the ED visits classified as DAWN cases in the selected hospitals.

The Drug Abuse Warning Network (DAWN) is a nationally representative public health surveillance system that has monitored drug related emergency department (ED) visits to hospitals since the early 1970s. First administered by the Drug Enforcement Administration (DEA) and the National Institute on Drug Abuse (NIDA), the responsibility for DAWN now rests with the Substance Abuse and Mental Health Services Administration's (SAMHSA) Center for Behavioral Health Statistics and Quality (CBHSQ). Over the years, the exact survey methodology has been adjusted to improve the quality, reliability, and generalizability of the information produced by DAWN. The current approach was first fully implemented in the 2004 data collection year.

DAWN relies on a longitudinal probability sample of hospitals located throughout the United States. To be eligible for selection into the DAWN sample, a hospital must be a non-Federal, short-stay, general surgical and medical hospital located in the United States, with at least one 24-hour ED. DAWN cases are identified by the systematic review of ED medical records in participating hospitals. The unit of analysis is any ED visit involving recent drug use. DAWN captures both ED visits that are directly caused by drugs and those in which drugs are a contributing factor but not the direct cause of the ED visit. The reason a patient used a drug is not part of the criteria for considering a visit to be drug-related. Therefore, all types of drug-related events are included: drug misuse or abuse, accidental drug ingestion, drug-related suicide attempts, malicious drug poisonings, and adverse reactions. DAWN does not report medications that are unrelated to the visit.

The DAWN public-use dataset provides information for all types of drugs, including illegal drugs, prescription drugs, over-the-counter medications, dietary supplements, anesthetic gases, substances that have psychoactive effects when inhaled, alcohol when used in combination with other drugs (all ages), and alcohol alone (only for patients aged 20 or younger). Public-use dataset variables describe and categorize up to 22 drugs contributing to the ED visit, including toxicology confirmation and route of administration. Administrative variables specify the type of case, case disposition, categorized episode time of day, and quarter of year. Metropolitan area is included for represented metropolitan areas. Created variables include the number of unique drugs reported and case-level indicators for alcohol, non-alcohol illicit substances, any pharmaceutical, non-medical use of pharmaceuticals, and all misuse and abuse of drugs. Demographic items include age category, sex, and race/ethnicity. Complex sample design and weighting variables are included to calculate various estimates of drug-related ED visits for the Nation as a whole, as well as for specific metropolitan areas, from the ED visits classified as DAWN cases in the selected hospitals.

The Drug Abuse Warning Network (DAWN) is a nationally representative public health surveillance system that has monitored drug related emergency department (ED) visits to hospitals since the early 1970s. First administered by the Drug Enforcement Administration (DEA) and the National Institute on Drug Abuse (NIDA), the responsibility for DAWN now rests with the Substance Abuse and Mental Health Services Administration's (SAMHSA) Center for Behavioral Health Statistics and Quality (CBHSQ). Over the years, the exact survey methodology has been adjusted to improve the quality, reliability, and generalizability of the information produced by DAWN. The current approach was first fully implemented in the 2004 data collection year.

DAWN relies on a longitudinal probability sample of hospitals located throughout the United States. To be eligible for selection into the DAWN sample, a hospital must be a non-Federal, short-stay, general surgical and medical hospital located in the United States, with at least one 24-hour ED. DAWN cases are identified by the systematic review of ED medical records in participating hospitals. The unit of analysis is any ED visit involving recent drug use. DAWN captures both ED visits that are directly caused by drugs and those in which drugs are a contributing factor but not the direct cause of the ED visit. The reason a patient used a drug is not part of the criteria for considering a visit to be drug-related. Therefore, all types of drug-related events are included: drug misuse or abuse, accidental drug ingestion, drug-related suicide attempts, malicious drug poisonings, and adverse reactions. DAWN does not report medications that are unrelated to the visit.

The DAWN public-use dataset provides information for all types of drugs, including illegal drugs, prescription drugs, over-the-counter medications, dietary supplements, anesthetic gases, substances that have psychoactive effects when inhaled, alcohol when used in combination with other drugs (all ages), and alcohol alone (only for patients aged 20 or younger). Public-use dataset variables describe and categorize up to 22 drugs contributing to the ED visit, including toxicology confirmation and route of administration. Administrative variables specify the type of case, case disposition, categorized episode time of day, and quarter of year. Metropolitan area is included for represented metropolitan areas. Created variables include the number of unique drugs reported and case-level indicators for alcohol, non-alcohol illicit substances, any pharmaceutical, non-medical use of pharmaceuticals, and all misuse and abuse of drugs. Demographic items include age category, sex, and race/ethnicity. Complex sample design and weighting variables are included to calculate various estimates of drug-related ED visits for the Nation as a whole, as well as for specific metropolitan areas, from the ED visits classified as DAWN cases in the selected hospitals.

The Drug Abuse Warning Network (DAWN) is a nationally representative public health surveillance system that has monitored drug related emergency department (ED) visits to hospitals since the early 1970s. First administered by the Drug Enforcement Administration (DEA) and the National Institute on Drug Abuse (NIDA), the responsibility for DAWN now rests with the Substance Abuse and Mental Health Services Administration's (SAMHSA) Center for Behavioral Health Statistics and Quality (CBHSQ). Over the years, the exact survey methodology has been adjusted to improve the quality, reliability, and generalizability of the information produced by DAWN. The current approach was first fully implemented in the 2004 data collection year.

DAWN relies on a longitudinal probability sample of hospitals located throughout the United States. To be eligible for selection into the DAWN sample, a hospital must be a non-Federal, short-stay, general surgical and medical hospital located in the United States, with at least one 24-hour ED. DAWN cases are identified by the systematic review of ED medical records in participating hospitals. The unit of analysis is any ED visit involving recent drug use. DAWN captures both ED visits that are directly caused by drugs and those in which drugs are a contributing factor but not the direct cause of the ED visit. The reason a patient used a drug is not part of the criteria for considering a visit to be drug-related. Therefore, all types of drug-related events are included: drug misuse or abuse, accidental drug ingestion, drug-related suicide attempts, malicious drug poisonings, and adverse reactions. DAWN does not report medications that are unrelated to the visit.

The DAWN public-use dataset provides information for all types of drugs, including illegal drugs, prescription drugs, over-the-counter medications, dietary supplements, anesthetic gases, substances that have psychoactive effects when inhaled, alcohol when used in combination with other drugs (all ages), and alcohol alone (only for patients aged 20 or younger). Public-use dataset variables describe and categorize up to 22 drugs contributing to the ED visit, including toxicology confirmation and route of administration. Administrative variables specify the type of case, case disposition, categorized episode time of day, and quarter of year. Metropolitan area is included for represented metropolitan areas. Created variables include the number of unique drugs reported and case-level indicators for alcohol, non-alcohol illicit substances, any pharmaceutical, non-medical use of pharmaceuticals, and all misuse and abuse of drugs. Demographic items include age category, sex, and race/ethnicity. Complex sample design and weighting variables are included to calculate various estimates of drug-related ED visits for the Nation as a whole, as well as for specific metropolitan areas, from the ED visits classified as DAWN cases in the selected hospitals.

The Drug Use Among Young Indians: Epidemiology and Prediction study is an annual surveillance effort assessing the levels and patterns of substance use among American Indian (AI) adolescents attending schools on or near reservations. In addition to annual epidemiology of substance use, data pertaining to the normative environment for adolescent substance use were also obtained. For this data collection data comes from annual in-school surveys completed between the years 1993 to 2006, and 2009 to 2013. Students completed the surveys at school during a specified class period. The dataset contains 534 variables for 26,451 students in grades 7 to 12.

These data are part of NACJD's Fast Track Release and are distributed as they were received from the data depositor. The files have been zipped by NACJD for release, but not checked or processed except for the removal of direct identifiers. Users should refer to the accompanying readme file for a brief description of the files available with this collection and consult the investigator(s) if further information is needed.

Teenage adolescent females residing in Baltimore, Maryland who were involved in a relationship with a history of violence were sought after to participate in this research study. Respondents were interviewed and then followed through daily diary entries for several months. The aim of the research was to understand the context regarding teen dating violence (TDV). Prior research on relationship context has not focused on minority populations; therefore, the focus of this project was urban, predominantly African American females.

The available data in this collection includes three SAS (.sas7bdat) files and a single SAS formats file that contains variable and value label information for all three data files. The three data files are:

• final_baseline.sas7bdat (157 cases / 252 variables)
• final_partnergrid.sas7bdat (156 cases / 76 variables)
• hart_final_sas7bdata (7004 cases / 23 variables)

This study is part of the Seek, Test, Treat and Retain (STTR) Collaboration Project that involved over twenty studies in the fields of HIV and drug abuse. All studies were independently developed, but were chosen for the collaboration because they focused on one or more steps of the HIV treatment cascade: Seek, Test, Treat and Retain. As part of STTR Collaboration Project, the studies were grouped into Criminal Justice-related studies and Vulnerable Population-related studies. The data collected by these studies included twelve common domains (e.g., Demographic characteristics, Mental Health) in each of which a shared questionnaire or instrument was taken up by the studies and adapted to fit the study.

This study was a Randomized Controlled Trial (RCT) of a peer-based health system navigation intervention among individuals assigned to the intervention group compared with those assigned to the control group (usual care transitional management services). Baseline interviews were conducted during incarceration while the follow-up interviews were conducted at months 2, 6 and 12 following release from jail to the community. For participants who were re-incarcerated during, interviews were conducted in the jail setting to ensure high study retention. The goal was to improve engagement and retention in HIV care.